- A report by the Commons Health and Social Care Committee has warned that NHS plans to distribute the weight-loss drug Mounjaro are ‘unambitious’.
- Only about six per cent of eligible patients, roughly 220,000 of the 2.8 million who qualify, will receive the drug via the NHS across its initial three years.
- MPs warned that restricted NHS access has created a two-tier system where treatment depends on the ability to pay, entrenching health inequalities.
- Committee chairwoman Layla Moran urged the government to treat obesity as a chronic condition similar to diabetes and host an urgent summit to accelerate GLP-1 drug rollout.
- Pharmacy experts added that slow NHS provision risks pushing desperate patients towards dangerous black-market alternatives.
IN FULL
